The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
Carisma to receive US $ 45 million up-front cash payment and investment by Moderna in the form of a US $ 35 million convertible note
Subscribe To Our Newsletter & Stay Updated
